Is neuroAD right for all AD patients?
The neuroAD technology is currently CE-cleared for “the treatment of mild to moderate AD.”
Is neuroAD contraindicated for use in conjunction with ChEI treatment?
Preliminary clinical trial results indicated that the neuroAD system potentially delivers superior results than ChEIs. However, neuroAD treatments can be administered safely in conjunction with current ChEI drug therapies, so that patient can enjoy the benefits of both. And unlike ChEI drugs, no adverse side effects were reported with the neuroAD system.
Where have the trial results been published?
The results of the first generation device were published in the Journal of Neural Transmission.
Prof. Jose M. Rabey, a member of Neuronix’s Scientific Advisory Board led the trial.
Is neuroAD useful for other cognitive impairments?
neuroAD, based on Neuronix’s NICE™ technology, may potentially be useful for MCI or other forms of dementia. Development at Neuronix is ongoing and the potential for further applications certainly exists.
Is neuroAD available for patients today?
neuroAD is currently an investigational device in the U.S. and Europe, and the technology is currently cleared only in Europe. There are ongoing clinical trials throughout Europe, the U.S. and Israel. For information about opening new trial sites, or for information on current sites, please contact firstname.lastname@example.org
Who is behind the ongoing research and development?
Neuronix’s team of engineers, neuropsychologists, researchers and physicians developed this unique and breakthrough technology. In addition, the development team is supported by the company’s Scientific Advisory Board, which includes several of the world’s leading researchers in Neurology and Alzheimer’s Disease.
NeuroAD is an investigational device, currently not available in the USA